Latest ViaCyte Inc. Stories
SAN DIEGO, Aug.
NEW YORK, July 17, 2014 /PRNewswire/ -- JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research announced today ViaCyte, Inc., a leading regenerative medicine
SAN DIEGO, July 17, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, today announced that
SAN DIEGO, July 8, 2014 /PRNewswire/ -- ViaCyte, Inc.
SAN DIEGO, May 29, 2014 /PRNewswire/ -- ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with insulin-dependent diabetes,
-- Potentially transformative therapy for individuals with type 1 diabetes nearing major milestone -- NEW YORK and SAN DIEGO, Feb.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.